Olympus Scope Lawsuit: Duodenoscope, CRE Superbug, and MAJ-891 Recall Litigation Guide for Attorneys

Why Olympus scope litigation is the most attorney-friendly tort of 2026

Every mass tort lives on three questions: is there a confirmed defect, is there strong evidence the defendant knew, and is there a large, identifiable population of injured patients? Olympus scope litigation answers all three with unusual clarity.

The U.S. Senate HELP Committee confirmed more than 400 infections tied to contaminated Olympus duodenoscopes across 36+ U.S. hospitals, with at least 35 deaths. That was the 2016 baseline — years before the January 2025 recall of the MAJ-891 tubing set (120 additional injuries, 1 death), the June 2025 FDA import alert on 58 Olympus products, the October 2025 Urgent Field Safety Notice (2 additional deaths, 5 injuries), and the March 2026 Health Canada recall. The universe of exposed patients has grown continuously, not shrunk.

The knowledge evidence is arguably the strongest in any active product liability litigation. Internal Olympus communications produced in Bigler v. Olympus show the company identified the bacteria-trapping defect in the TJF-Q180V duodenoscope as early as 2012, warned European hospitals in 2013 and 2014, and delayed notifying U.S. hospitals until February 2015. In 2018, Olympus Medical Systems Corp. paid an $85 million criminal fine and pleaded guilty to failing to report device-related injuries to the FDA — a rare guilty plea from a major device manufacturer.

You almost never see this combination: a confirmed design defect, a criminal guilty plea, a sitting Senate committee investigation, and a fresh Class I recall — all on the same defendant, all still live in 2026.

For PI firms, the strategic question is not whether to run Olympus scope intake. It is how fast you can build a qualified pipeline before the market saturates.

The defect: why Olympus scopes trap bacteria after cleaning

Duodenoscopes are flexible, side-viewing endoscopes used in ERCP (Endoscopic Retrograde Cholangiopancreatography) procedures to access the bile and pancreatic ducts. Unlike standard gastroscopes, duodenoscopes have an elevator mechanism at the distal tip that allows the physician to angle catheters and guidewires into the ducts. That elevator mechanism — combined with the scope's narrow internal channels — is where the defect lives.

In the Olympus TJF-Q180V and TJF-160F designs, the elevator mechanism has tight crevices and sealed channels that standard reprocessing cycles cannot fully penetrate. Bacterial biofilm — especially carbapenem-resistant Enterobacteriaceae, or CRE — survives cleaning and is transmitted from patient to patient even when hospitals follow the manufacturer's reprocessing instructions perfectly.

This is not a user error. The FDA confirmed that Olympus's own reprocessing instructions, followed correctly, did not fully decontaminate the device. That finding is the backbone of design defect claims.

Why CRE infections are catastrophic

CRE is not a routine hospital-acquired infection. It is classified by the CDC as an "urgent threat" antibiotic-resistant organism. Invasive CRE infections carry a mortality rate of roughly 50%. Patients who survive often spend weeks in the ICU, undergo multiple surgeries to drain abscesses or resect infected tissue, and carry permanent organ damage.

For a patient who entered the hospital for a routine bile duct procedure and left septic, the damages are exactly the kind juries reward heavily. Combine severe physical injury with documented corporate concealment, and you have the facts of the $6.6 million Bigler verdict and the additional $250,000 in concealment sanctions.

The MAJ-891 recall and why it broadened the litigation

For years, Olympus scope litigation focused almost exclusively on duodenoscopes. The January 2025 Class I recall of the MAJ-891 single-use tubing set changed that.

The MAJ-891 is used with Olympus endoscope irrigation pumps and is deployed across a broad range of endoscopic procedures — not just ERCP. Olympus initiated the recall after receiving 120 reports of injuries and 1 death linked to tubing failures that could contaminate the patient or procedure field. The FDA classified the recall as Class I, the most serious category, indicating a reasonable probability of serious injury or death.

The MAJ-891 recall matters strategically for three reasons:

• It expanded the device universe. Claims now reach cystoscopy, ureteroscopy, choledochoscopy, and hysteroscopy patients — not just ERCP patients.
• It added a second liability theory. The original duodenoscope claims rely on design defect. MAJ-891 adds a manufacturing defect and failure-to-warn theory tied to a specific Class I recall.
• It reset the statute of limitations for many claimants. Even patients whose original scope procedure was years ago may have fresh claims if a MAJ-891 tubing failure was involved.

The FDA's June 2025 import alert on 58 Olympus products — blocking entry of non-compliant devices into the U.S. — and the October 2025 Urgent Field Safety Notice reinforced the pattern. This is no longer a single-device litigation.

Government and regulatory record: unusually deep

The regulatory footprint on Olympus is one of the most extensive in any active tort. A concise timeline:

• 2012 — Virginia Mason Medical Center (Seattle) reports CRE outbreak linked to Olympus duodenoscopes. Olympus engineers internally confirm the defect.
• 2013–2014 — Olympus issues warnings to European hospitals about the reprocessing defect. U.S. hospitals are not notified.
• February 2015 — Olympus finally issues U.S. safety communication, three years after the defect was identified internally.
• 2016 — U.S. Senate HELP Committee releases its report confirming 400+ infections at 36+ hospitals and at least 35 deaths.
• 2018 — Olympus Medical Systems Corp. pleads guilty and pays an $85 million criminal fine for failing to report device-related injuries to the FDA.
• January 2025 — Class I recall of MAJ-891 tubing sets after 120 injuries and 1 death.
• June 2025 — FDA import alert on 58 Olympus products.
• October 2025 — Urgent Field Safety Notice: 2 additional deaths, 5 injuries.
• March 2026 — Health Canada recall extends the international regulatory record.

For plaintiff firms, that timeline is a gift. Almost every element of notice, concealment, and continuing harm is documented in public record by federal agencies and a Senate committee. Discovery costs are lower, and motions to dismiss face an uphill climb.

The defendant: can Olympus pay?

A common concern in mass tort planning is whether the defendant can actually fund settlements at scale. With Olympus, the answer is yes.

• $6.75 billion in annual revenue (Olympus Corp. consolidated).
• ~$13.5 billion market capitalization.
• Roughly 85% of the U.S. duodenoscope market — which translates to substantial insurance coverage and a deep financial interest in resolving litigation to protect ongoing business.
• Established history of paying — the 2018 $85 million criminal fine was paid, and the Bigler $6.6 million verdict plus $250,000 sanctions were paid.

The defendant profile is the inverse of many emerging torts where plaintiff firms worry about bankruptcy protection limiting recovery. Olympus is solvent, cash-flowing, and publicly traded.

Qualifying criteria: who is a claimant

Our intake criteria for Olympus scope cases are tight enough to avoid wasting firm resources on weak claims, and broad enough to capture the expanded device universe after MAJ-891.

Required

• The patient underwent a procedure using an Olympus duodenoscope (TJF-Q180V, TJF-160F), cystoscope, ureteroscope, choledochoscope, or hysteroscope — or a procedure involving the MAJ-891 tubing set — at a U.S. hospital or ambulatory surgical center from 2012 onward.
• The patient was diagnosed with a bacterial infection within approximately 30 days of the scope procedure. Qualifying diagnoses include CRE, sepsis, bacteremia, E. coli, Klebsiella, Pseudomonas, cholangitis, or post-procedure urinary tract infection.
• The infection required hospitalization, ICU admission, or extended medical treatment. Outpatient antibiotics with full recovery in a week is generally not a viable mass tort claim.

Strongly preferred

• Hospital records confirming the Olympus device was used (scope serial number, procedure note, reprocessing log).
• Culture results identifying the causative organism, especially CRE.
• Evidence of permanent injury — organ damage, loss of function, additional surgery — or wrongful death.

Exclusions

• Infections with clear alternative causation unrelated to the scope procedure.
• Claims that fall outside the applicable state statute of limitations with no discovery rule argument available.
• Claimants who already have representation from another firm for the same claim.

Case value framework

Settlement values are still being established for the expanded litigation, but early indicators from the original duodenoscope cases and the Bigler verdict support a tiered model:

• Tier 1 — Wrongful death or catastrophic outcome: Seven-figure range. The Bigler case ($6.6M verdict plus $250K concealment sanctions) is the reference point. Cases with concealment findings and documented notice failures support the upper end.
• Tier 2 — Severe CRE or sepsis with ICU admission: High six figures. Multi-week hospitalization, organ involvement, and documented long-term consequences drive value.
• Tier 3 — Hospitalized infection with recovery: Mid six figures. Shorter hospitalization without permanent injury anchors this tier.
• Tier 4 — Documented but lower-severity infection: Low six figures or below. These cases are best held for aggregated resolution.

Economic damages (medical bills, lost wages) tend to be significant because CRE treatment is expensive and prolonged. Non-economic damages benefit from the strong concealment narrative — a jury hearing about a 2012 internal defect report followed by a 2015 U.S. warning tends to award generously.

Statute of limitations and the discovery rule

Most states apply a 2 to 4 year statute of limitations for personal injury and product liability claims, running from the date of injury or the date the claimant reasonably should have discovered the connection between the injury and the defect.

The discovery rule is particularly important in Olympus scope cases because:

• The defect was not disclosed to U.S. hospitals until February 2015.
• Many patients were told their infections were generic hospital-acquired infections, not device-related.
• The MAJ-891 recall was not announced until January 2025.

Firms should screen older cases carefully and run a discovery rule analysis early. Wrongful death limitations generally run from the date of death, which can preserve claims where the underlying procedure is outside the standard personal injury limitations window.

How to build Olympus scope intake

Olympus scope intake is medically complex. Your intake team needs to confirm both the procedure record and the infection record — which typically come from different providers, sometimes different health systems. A practical intake script should flow like this:

Step 1 — Procedure confirmation

Did you undergo an endoscopic procedure — specifically an ERCP, cystoscopy, ureteroscopy, choledochoscopy, or hysteroscopy — at a U.S. hospital or surgical center from 2012 to the present? Capture the facility name, the approximate date, and the type of procedure. If the claimant is unsure whether the scope was an Olympus device, note that most U.S. duodenoscopes are Olympus and proceed.

Step 2 — Infection confirmation

Did you receive a diagnosis of a bacterial infection, sepsis, CRE, or a bloodstream infection within approximately 30 days of that procedure? Capture the diagnosis, the treating facility, and whether hospitalization or ICU admission was required.

Step 3 — Documentation collection

Explain what is needed: procedure records (operative note, reprocessing log if available), infection diagnosis records (culture results, discharge summary), and hospitalization records. Provide secure upload links and HIPAA authorizations for record retrieval. Many claimants will need the firm's records team to retrieve documents on their behalf.

Step 4 — Conflict and duplicate check

Verify the claimant has not already retained another firm for this claim. Olympus scope outreach is active across multiple firms, so duplicate signings are a real risk.

Step 5 — Retainer execution

Execute a contingency retainer via e-signature during the initial call. Explain the mass tort process, the expected timeline, and the firm's role in pursuing the claim. Firms that defer retainer execution lose meaningful conversion.

If you do not have a standing mass tort intake operation, Olympus scope is not the tort to learn on — the medical complexity rewards firms with experienced intake teams. Outsourced intake partners with tort-specific training can be a faster path than building from scratch.

Marketing and lead acquisition strategy

Olympus scope lead acquisition is different from broad consumer torts like hair relaxer or Roundup. The qualifying population is smaller, more clinically specific, and often difficult to reach through mass media alone. Effective channels:

• Targeted search: Patients who experienced post-ERCP infections search for terms like "duodenoscope infection," "CRE after ERCP," and "Olympus scope lawsuit." These are high-intent, lower-volume queries.
• Medical record partnerships: Claimants often know they had a bad outcome but do not know the mechanism. Partnerships with medical record retrieval services can identify device-related infections in discharge records.
• Support group outreach: CRE survivor groups and sepsis support communities contain high concentrations of qualifying claimants.
• Physician referrals: Infectious disease specialists and gastroenterologists frequently encounter post-procedure infections and can be a steady referral source for firms with established relationships.
• TV and broad digital: Useful for volume but needs tight screening — untargeted Olympus scope TV campaigns generate heavy unqualified lead volume.

Cost per qualified Olympus scope lead tends to run higher than broad consumer torts but settles more reliably, and the case values are strong enough that the unit economics hold up.

What to do in the next 30 days

If your firm is considering Olympus scope litigation, the next 30 days should include:

1. Ethical review and conflict check. Confirm the firm is eligible to take on the case type in every state where you plan to solicit.
2. Intake criteria freeze. Adopt the qualifying criteria above or a variant your lead counsel signs off on. Everyone on the team screens to the same criteria.
3. Records retrieval capacity. Stand up a medical records team — internal or outsourced — capable of pulling scope procedure notes and infection diagnosis records from multiple health systems.
4. Marketing launch. Start with targeted search and support group outreach. Scale to TV only after intake conversion metrics stabilize.
5. Lead partner. If you do not want to build marketing in-house, engage an exclusive lead partner with Olympus-specific intake screening. Non-exclusive lead partners are a fast way to burn spend on duplicates.

Frequently asked questions

The bottom line for mass tort firms

Olympus scope litigation has the three elements that make a mass tort worth pursuing: a confirmed defect backed by federal findings, unusually strong concealment evidence, and a solvent defendant. The expansion from duodenoscopes to cystoscopes, ureteroscopes, choledochoscopes, and hysteroscopes — triggered by the MAJ-891 recall, the FDA import alert, and the Urgent Field Safety Notice — has broadened the claimant universe faster than most firms have responded.

Firms that build tight intake criteria, invest in records retrieval, and partner with exclusive lead sources will sign the strongest cases before the market saturates. The Bigler verdict is the floor on what these cases can be worth with the right facts. The only question is how quickly you move.